Note 9 - Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

	Three Months Ended March 31, 2019
	Clinical Development			Device			Total
Net revenues	$	11,000		$	2,951,000		$	2,962,000
Cost of revenues		43,000			1,661,000			1,704,000
Gross profit		(32,000	)		1,290,000			1,258,000
Operating expenses		471,000			1,693,000			2,164,000
Operating loss	$	(503,000	)	$	(403,000	)	$	(906,000	)
Depreciation and amortization	$	95,000		$	117,000		$	212,000
Stock-based compensation expense	$	54,000		$	27,000		$	81,000
Goodwill		--		$	781,000		$	781,000
Total assets	$	4,281,000		$	11,349,000		$	15,630,000

	Three Months Ended March 31, 2018
	Clinical Development			Device			Total
Net revenues	$	62,000		$	1,805,000		$	1,867,000
Cost of revenues		71,000			1,444,000			1,515,000
Gross profit		(9,000	)		361,000			352,000
Operating expenses		1,179,000			2,429,000			3,608,000
Operating loss	$	(1,188,000	)	$	(2,068,000	)	$	(3,256,000	)
Depreciation and amortization	$	68,000		$	91,000		$	159,000
Stock-based compensation expense	$	98,000		$	39,000		$	137,000
Goodwill	$	13,195,000		$	781,000		$	13,976,000
Total assets	$	38,941,000		$	11,240,000		$	50,181,000